Plasmodium Falciparum Susceptibility to Standard and Potential Anti-malarial Drugs in Dakar, Senegal, During the 2013-2014 Malaria Season

Overview

Journal Malar J

Publisher Biomed Central

Specialty Tropical Medicine

Date 2015 Apr 8

PMID 25849097

Citations 18

Authors

Becaye Fall

Cheikhou Camara

Mansour Fall

Aminata Nakoulima

Pierre Dionne

Bakary Diatta

Yaya Dieme

Boubacar Wade

Bruno Pradines

Affiliations

Soon will be listed here.

Abstract

Background: In 2006, the Senegalese National Malaria Control Programme recommended artemisinin-based combination therapy (ACT) as the first-line treatment for uncomplicated malaria. Since the introduction of ACT, there have been very few reports on the level of Plasmodium falciparum resistance to anti-malarial drugs. An ex vivo susceptibility study was conducted on local isolates obtained from the Hôpital Principal de Dakar (Dakar, Senegal) from November 2013 to January 2014.

Methods: Eighteen P. falciparum isolates were sussessfully assessed for ex vivo susceptibility to chloroquine (CQ), quinine (QN), monodesethylamodiaquine (MDAQ), the active metabolite of amodiaquine, mefloquine (MQ), lumefantrine (LMF), artesunate (AS), dihydroartemisinin (DHA), the active metabolite of artemisinin derivatives, pyronaridine (PND), piperaquine (PPQ), and, Proveblue (PVB), a methylene blue preparation, using the HRP2-based ELISA test.

Results: The prevalence of isolates with reduced susceptibility was 55.6% for MQ, 50% for CQ, 5.6% for QN and MDAQ, and 0% for DHA, AS and LMF. The mean IC₅₀ for PND, PPQ and PVB were 5.8 nM, 32.2 nM and 5.3 nM, respectively.

Conclusions: The prevalence of isolates with a reduced susceptibility to MQ remains high and stable in Dakar. Since 2004, the prevalence of CQ resistance decreased, but rebounded in 2013 in Dakar. PND, PPQ and PVB showed high in vitro activity in P. falciparum parasites from Dakar.

Citing Articles

Methylene Blue-Based Combination Therapy with Amodiaquine Prevents Severe Malaria in an Experimental Rodent Model.

Dormoi J, Amalvict R, Gendrot M, Pradines B Pharmaceutics. 2022; 14(10).

PMID: 36297466 PMC: 9611243. DOI: 10.3390/pharmaceutics14102031.

Design, Synthesis, and Development of 4-[(7-Chloroquinoline-4-yl)amino]phenol as a Potential SARS-CoV-2 Mpro Inhibitor.

Guevara-Pulido J, Jimenez R, Morantes S, Jaramillo D, Acosta-Guzman P ChemistrySelect. 2022; 7(15):e202200125.

PMID: 35601684 PMC: 9111044. DOI: 10.1002/slct.202200125.

Absence of Association between Methylene Blue Reduced Susceptibility and Polymorphisms in 12 Genes Involved in Antimalarial Drug Resistance in African .

Gendrot M, Delandre O, Robert M, Foguim F, Benoit N, Amalvict R Pharmaceuticals (Basel). 2021; 14(4).

PMID: 33918981 PMC: 8069138. DOI: 10.3390/ph14040351.

Prevalence of pfk13 and pfmdr1 polymorphisms in Bounkiling, Southern Senegal.

Ahouidi A, Oliveira R, Lobo L, Diedhiou C, Mboup S, Nogueira F PLoS One. 2021; 16(3):e0249357.

PMID: 33770151 PMC: 7996989. DOI: 10.1371/journal.pone.0249357.

Methylene blue inhibits replication of SARS-CoV-2 in vitro.

Gendrot M, Andreani J, Duflot I, Boxberger M, Bideau M, Mosnier J Int J Antimicrob Agents. 2020; 56(6):106202.

PMID: 33075512 PMC: 7566888. DOI: 10.1016/j.ijantimicag.2020.106202.

References

AdeMowo O, Nneji C, Adedapo A . In vitro antimalarial activity of methylene blue against field isolates of Plasmodium falciparum from children in Southwest Nigeria. Indian J Med Res. 2007; 126(1):45-9. View

Pradines B, Tall A, Parzy D, Spiegel A, Fusai T, Hienne R . In-vitro activity of pyronaridine and amodiaquine against African isolates (Senegal) of Plasmodium falciparum in comparison with standard antimalarial agents. J Antimicrob Chemother. 1998; 42(3):333-9. DOI: 10.1093/jac/42.3.333. View

Suwanarusk R, Russell B, Ong A, Sriprawat K, Chu C, PyaePhyo A . Methylene blue inhibits the asexual development of vivax malaria parasites from a region of increasing chloroquine resistance. J Antimicrob Chemother. 2014; 70(1):124-9. PMC: 4267499. DOI: 10.1093/jac/dku326. View

Palmieri F, Petrosillo N, Paglia M, Conte A, Goletti D, Pucillo L . Genetic confirmation of quinine-resistant Plasmodium falciparum malaria followed by postmalaria neurological syndrome in a traveler from Mozambique. J Clin Microbiol. 2004; 42(11):5424-6. PMC: 525244. DOI: 10.1128/JCM.42.11.5424-5426.2004. View

Sarr O, Myrick A, Daily J, Diop B, Dieng T, Ndir O . In vivo and in vitro analysis of chloroquine resistance in Plasmodium falciparum isolates from Senegal. Parasitol Res. 2005; 97(2):136-40. PMC: 2579896. DOI: 10.1007/s00436-005-1406-7. View

Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B . Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet. 2005; 366(9501):1960-3. DOI: 10.1016/S0140-6736(05)67787-2. View

Pradines B, Tall A, Ramiandrasoa F, Spiegel A, Sokhna C, Fusai T . In vitro activity of iron-binding compounds against Senegalese isolates of Plasmodium falciparum. J Antimicrob Chemother. 2006; 57(6):1093-9. DOI: 10.1093/jac/dkl117. View

Brasseur P, Guiguemde R, Diallo S, Guiyedi V, Kombila M, Ringwald P . Amodiaquine remains effective for treating uncomplicated malaria in west and central Africa. Trans R Soc Trop Med Hyg. 2000; 93(6):645-50. DOI: 10.1016/s0035-9203(99)90083-4. View

Pradines B, Tall A, Rogier C, Spiegel A, Mosnier J, Marrama L . In vitro activities of ferrochloroquine against 55 Senegalese isolates of Plasmodium falciparum in comparison with those of standard antimalarial drugs. Trop Med Int Health. 2002; 7(3):265-70. DOI: 10.1046/j.1365-3156.2002.00848.x. View

10.

Gari-Toussaint M, Pradines B, Mondain V, Keundjian A, Dellamonica P, Le Fichoux Y . [Senegal and malaria. True prophylactic failure of mefloquine]. Presse Med. 2002; 31(24):1136. View

11.

Thomas S, Ndir O, Dieng T, Mboup S, Wypij D, Maguire J . In vitro chloroquine susceptibility and PCR analysis of pfcrt and pfmdr1 polymorphisms in Plasmodium falciparum isolates from Senegal. Am J Trop Med Hyg. 2002; 66(5):474-80. DOI: 10.4269/ajtmh.2002.66.474. View

12.

Lambros C, Vanderberg J . Synchronization of Plasmodium falciparum erythrocytic stages in culture. J Parasitol. 1979; 65(3):418-20. View

13.

Brandicourt O, Druilhe P, Diouf F, Brasseur P, Turk P, Danis M . Decreased sensitivity to chloroquine and quinine of some Plasmodium falciparum strains from Senegal in September 1984. Am J Trop Med Hyg. 1986; 35(4):717-21. DOI: 10.4269/ajtmh.1986.35.717. View

14.

Hatin I, Trape J, Legros F, Bauchet J, Le Bras J . Susceptibility of Plasmodium falciparum strains to mefloquine in an urban area in Senegal. Bull World Health Organ. 1992; 70(3):363-7. PMC: 2393281. View

15.

Jelinek T, Schelbert P, Loscher T, Eichenlaub D . Quinine resistant falciparum malaria acquired in east Africa. Trop Med Parasitol. 1995; 46(1):38-40. View

16.

Bogreau H, Renaud F, Bouchiba H, Durand P, Assi S, Henry M . Genetic diversity and structure of African Plasmodium falciparum populations in urban and rural areas. Am J Trop Med Hyg. 2006; 74(6):953-9. View

17.

Henry M, Diallo I, Bordes J, Ka S, Pradines B, Diatta B . Urban malaria in Dakar, Senegal: chemosusceptibility and genetic diversity of Plasmodium falciparum isolates. Am J Trop Med Hyg. 2006; 75(1):146-51. View

18.

Pradines B, Mamfoumbi M, Tall A, Sokhna C, Koeck J, Fusai T . In vitro activity of tafenoquine against the asexual blood stages of Plasmodium falciparum isolates from Gabon, Senegal, and Djibouti. Antimicrob Agents Chemother. 2006; 50(9):3225-6. PMC: 1563556. DOI: 10.1128/AAC.00777-06. View

19.

Noranate N, Durand R, Tall A, Marrama L, Spiegel A, Sokhna C . Rapid dissemination of Plasmodium falciparum drug resistance despite strictly controlled antimalarial use. PLoS One. 2007; 2(1):e139. PMC: 1764034. DOI: 10.1371/journal.pone.0000139. View

20.

Sarr O, Ahouidi A, Ly O, Daily J, Ndiaye D, Ndir O . Mutations in PFCRT K76T do not correlate with sulfadoxine-pyrimethamine-amodiaquine failure in Pikine, Senegal. Parasitol Res. 2008; 103(4):765-9. PMC: 2583234. DOI: 10.1007/s00436-008-1038-9. View